World · India Bureau
NIT, IISER researchers develop patented oral cancer treatment formulation
Scientists from two premier Indian research institutions have secured a patent for a novel oral cancer formulation derived from cotarnine. The development marks progress in domestic cancer therapeutics research, though additional preclinical studies are required before clinical applications.
LSN India ·
Researchers at the National Institute of Technology and the Indian Institute of Science Education and Research have patented a new formulation based on cotarnine, a naturally occurring alkaloid, targeting oral cancer treatment. The patented compound has demonstrated activity against oral cancer cells in laboratory studies, according to the research team.
Oral cancer represents a significant health burden in India, where tobacco and betel nut consumption remain widespread risk factors. The development of indigenous therapeutic options could potentially address treatment gaps in the country's oncology sector.
The research team emphasized that while initial results are promising, the formulation requires extensive further investigation. Preclinical studies must establish the compound's safety profile and confirm its efficacy before it can advance toward clinical trial stages.
The patent represents a collaborative effort between the two institutions to develop homegrown solutions for cancer treatment. Such developments strengthen India's research capabilities in pharmaceutical innovation and potentially reduce dependence on imported therapeutic agents for cancer management.